APA (7th ed.) Citation

Vale, C. L., Fisher, D. J., Godolphin, P. J., Rydzewska, L. H., Boher, J., Burdett, S., . . . Tierney, J. F. (2023). Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: A systematic review and meta-analysis of individual participant data from randomised trials. The lancet oncology, 24(7), 783-797. https://doi.org/10.1016/S1470-2045(23)00230-9

Chicago Style (17th ed.) Citation

Vale, Claire L., et al. "Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials." The Lancet Oncology 24, no. 7 (2023): 783-797. https://doi.org/10.1016/S1470-2045(23)00230-9.

MLA (9th ed.) Citation

Vale, Claire L., et al. "Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials." The Lancet Oncology, vol. 24, no. 7, 2023, pp. 783-797, https://doi.org/10.1016/S1470-2045(23)00230-9.